The Beauty Health Company(SKIN)Earnings, Financials & Key RatiosThe Beauty Health Company (SKIN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
combined with a debt-to-equity ratio of 6.65 and a 6.7% revenue contraction in 2026Q1, indicates a high-risk profile that outweighs current valuation multiples.
The Beauty Health Company (SKIN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
The Beauty Health Company (SKIN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.05vs $0.09+44.4% | $65Mvs $66M-2.1% |
| Q2 2026 | Mar 12, 2026 | $0.06vs $0.07+14.3% | $82Mvs $78M+5.4% |
| Q4 2025 | Nov 6, 2025 | $0.09vs $0.08-12.5% | $71Mvs $78M-9.5% |
| Q3 2025 | Aug 7, 2025 | $0.03vs $0.06+150.0% | $78Mvs $68M+14.4% |
Recent stock market news and headlines for The Beauty Health Company (SKIN)
SkinStylus SteriLock MicroSystem Now the Only Microneedling Device with Indications for Facial Acne Scars, Periorbital Wrinkles, and Abdominal Scars
Key metrics vs top competitors for The Beauty Health Company (SKIN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.11 | $143.86M | -6.94 | -10.02% | -3.16% | -16.86% | — | |
| $75.34 | $4.48B | 171.23 | 24.59% | 3.34% | 5.16% | — | |
| $122.25 | $3.92B | 23.33 | 2.49% | 13.46% | 18.37% | — | |
| $2.23 | $1.96B | -5.07 | -3.68% | -9.26% | -14.13% | — | |
| $5.17 | $251.01M | 1.63 | -14.26% | 3.78% | 6.84% | — | |
| $22.38 | $413.2M | 38.59 | 8.28% | 0.96% | 1.51% | — |
The Beauty Health Company (SKIN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
The Beauty Health Company (SKIN) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 12, 2026·SEC
May 7, 2026·SEC
May 6, 2026·SEC
Get notified when SKIN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
The Beauty Health Company (SKIN) stock FAQ — growth, dividends, profitability & financials explained
The Beauty Health Company (SKIN) reported $296.1M in revenue for fiscal year 2025. This represents a 78% increase from $166.6M in 2019.
The Beauty Health Company (SKIN) saw revenue decline by 10.0% over the past year.
The Beauty Health Company (SKIN) reported a net loss of $6.0M for fiscal year 2025.
The Beauty Health Company (SKIN) has a return on equity (ROE) of -16.9%. Negative ROE indicates the company is unprofitable.
The Beauty Health Company (SKIN) generated $28.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
